Lenalidomide-Associated ITP
Case Reports in Hematology · 2011
DOI: 10.1155/2011/638020 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Hematology, 2011. Verfasst von Christina I Herold und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
Autor:innen und Institutionen
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Herold, C. I., Gasparetto, C., & Arepally, G. M. (2011). Lenalidomide-Associated ITP. Case Reports in Hematology. https://doi.org/10.1155/2011/638020
Vancouver
Herold CI, Gasparetto C, Arepally GM. Lenalidomide-Associated ITP. Case Reports in Hematology. 2011. doi:10.1155/2011/638020
BibTeX
@article{Herold2011,
author = {Herold, Christina I and Gasparetto, Cristina and Arepally, Gowthami M},
title = {Lenalidomide-Associated ITP},
journal = {Case Reports in Hematology},
year = {2011},
doi = {10.1155/2011/638020}
}
EUVIMED